<html>
<head>
<title>French study finds anti-malarial and antibiotic combo could reduce COVID-19 duration • TechCrunch</title>
<link href="../Styles/Style.css" type="text/css" rel="stylesheet"/>
</head>
<body>
<h1 class="translated">法国研究发现抗疟药和抗生素组合可以减少新冠肺炎持续时间</h1>
<blockquote>原文：<a href="https://web.archive.org/web/https://techcrunch.com/2020/03/19/french-study-finds-anti-malarial-and-antibiotic-combo-could-reduce-covid-19-duration/">https://web.archive.org/web/https://techcrunch.com/2020/03/19/french-study-finds-anti-malarial-and-antibiotic-combo-could-reduce-covid-19-duration/</a></blockquote><div><header class="article__header ">
	<p class="article__title-wrapper">
						</p><h1 class="article__title translated">法国研究发现抗疟药和抗生素联合使用可以减少新冠肺炎持续时间</h1>
		

			
	
			
	</header>

			<div class="article-content">
				<p id="speakable-summary" class="translated">一项新的研究<a href="https://web.archive.org/web/20230127174231/https://www.mediterranee-infection.com/hydroxychloroquine-and-azithromycin-as-a-treatment-of-covid-19/">的结果发表在<em>国际抗菌剂杂志</em>的</a>上，该研究发现了早期证据，表明羟氯喹(商品名为 Plaqenuil 的流行抗疟疾药物)和抗生素阿奇霉素(又名 Zithromax 或 Azithrocin)的组合在治疗新冠肺炎冠状病毒和减少病毒在患者体内的持续时间方面可能特别有效。</p>
<p class="translated">研究人员对 30 名确诊的新冠肺炎患者进行了研究，分别用羟氯喹单独治疗、药物和抗生素的组合治疗，以及一组不接受任何治疗的对照组。该研究是在来自中国患者治疗的报告表明这种特殊组合在缩短患者感染持续时间方面有效后进行的。</p>
<p class="translated">研究中包括的患者组合包括 6 名没有任何症状的患者，22 名有上呼吸道症状(如打喷嚏、头痛和喉咙痛)的患者，以及 8 名有下呼吸道症状(主要是咳嗽)的患者。该研究的 30 名参与者中有 20 名接受了治疗，结果显示，尽管羟基氯喹单独作为一种治疗方法是有效的，但当与阿奇霉素联合使用时，它甚至更有效，并且效果显著。</p>
<p class="translated"><img decoding="async" loading="lazy" class="aligncenter size-full wp-image-1962332" src="../Images/1d42facd17684b855b08e4f40b055d1e.png" alt="" data-wp-editing="1" srcset="https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA-24-1038x553-1.jpg 1038w, https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA-24-1038x553-1.jpg?resize=150,80 150w, https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA-24-1038x553-1.jpg?resize=300,160 300w, https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA-24-1038x553-1.jpg?resize=768,409 768w, https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA-24-1038x553-1.jpg?resize=680,362 680w, https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA-24-1038x553-1.jpg?resize=50,27 50w" sizes="(max-width: 1024px) 100vw, 1024px" data-original-src="https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA-24-1038x553-1.jpg"/></p>
<p class="translated">这些结果代表了对少数患者的有限研究，但它们是有希望的，特别是当结合来自中国采用相同治疗方案的患者的早期报告时。全球研究人员正在测试一些潜在的治疗方法，包括以前在抗击埃博拉病毒、非典、艾滋病毒和其他全球疫情中使用的一系列药物。</p>
<p class="translated">迄今为止，还没有专门针对新冠肺炎的确认有效的治疗方法，但各地的监管机构和医学研究人员都在努力通过测试和批准程序，寻找至少可以缩短专利症状的持续时间或严重性的东西。疫苗开发也在进行中，但任何获得批准的有效新冠肺炎疫苗至少还需要 12-18 个月的时间，即使资源被重新用于在尽可能安全的情况下尽快开发疫苗。</p>
<p class="translated"><a href="https://web.archive.org/web/20230127174231/https://techcrunch.com/pages/covid-19-updates/"> <img decoding="async" src="../Images/3888995d8d0d3d0ba79ff8b6484ff82e.png" data-original-src="https://web.archive.org/web/20230127174231im_/https://techcrunch.com/wp-content/uploads/2020/03/covid-19-footer.png"/> </a></p>
			</div>

			</div>    
</body>
</html>